Ropinirole for the treatment of early Parkinson's disease

Neurology

Volumn 49, Issue 2, 1997, Pages 393-399

  Adler, C H ^a,j   Sethi, K D ^b   Hauser, R A ^c   Davis, T L ^d   Hammerstad, J P ^e   Bertoni, J ^f   Taylor, R L ^g   Sanchez Ramos, J ^h   O'Brien, C F ⁱ  

^a MAYO CLINIC   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VANDERBILT UNIVERSITY HOSPITAL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f CREIGHTON UNIVERSITY   (United States)

^g Taylor Medical Group   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ Colorado Neurological Institute ^*  (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ROPINIROLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; VERTIGO;

EID: 0030804074     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.393     Document Type: Article

References (31)

1. Blin JB, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
2. Mouradian MM, Chase TN. Levodopa response fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:378-385.
3. Horstink MWIM, Zijlmans JCM, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226.
4. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-1027.
5. Nutt JG. Management of parkinsonism and treatment of associated complications. Curr Opin Neurol 1995;8:327-330.
6. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S6-S12.
7. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19:108-112.
8. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm 1995;45(suppl): 187-195.
9. Ogawa N, Edamatsu R, Mizukawa K, Asanuma M, Kohno M, Mori A. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv Neurol 1993;60:243-250.
10. Fahn S, Bressman SB. Should levodopa therapy for parkinsonism be started early or late? Evidence against early treatment. Can J Neurol Sci 1984;11(suppl):200-205.
11. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995;310:575-579.
12. Rinne UK. Early dopamine agonist therapy in Parkinson's disease. Mov Disord 1989;4(suppl 1):S86-S94.
13. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
14. Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of "de novo" Parkinson's disease patients. Can J Neurol Sci 1987;14:576-580.
15. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-27.
16. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-910.
17. Brooks DJ, Torjanski N, Burn DJ. Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 1995;45(suppl):231-238.
18. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995;45(suppl 3):S28-S34.
19. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;1:44.
20. LeWitt PA, Calne DB. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981;1:44-45.
21. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
22. 2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
23. Fahn S, Elton RL, UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne D, eds. Recent Developments in Parkinson's Disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
24. CIOMS, International reporting of adverse drug reactions: Final report of the CIOMS Working Group. 1990.
25. Laroche J. An alternative analysis of motor score in the assessment of Parkinson's disease. In: Douglas J, ed. 1995 PSI conference report, Blackpool, UK Macclesfield: Statisticians in the Pharmaceutical Industry, 1996:52-53.
26. Comella CL, Stebbins GT, Brown-Toms H, Goetz CG. Physical therapy and Parkinson's disease. Neurology 1994;44:376-378.
27. Goetz CG. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990;40(suppl 3):50-54.
28. Montastruc JL, Rascol O, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs 1993;46:384-393.
29. Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988;36:67-82.
30. Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annu Rev Med 1993;44:431-440.
31. Peppe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in L-dopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.